List of Intermezzo drug patents

Intermezzo is owned by Purdue Pharma.

Intermezzo contains Zolpidem Tartrate.

Intermezzo has a total of 4 drug patents out of which 0 drug patents have expired.

Intermezzo was authorised for market use on 23 November, 2011.

Intermezzo is available in tablet;sublingual dosage forms.

Intermezzo can be used as method of treating middle-of-the-night insomnia, method for treating insomnia.

The generics of Intermezzo are possible to be released after 20 August, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7682628 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Feb, 2025

(2 years from now)

US8252809 PURDUE PHARMA Compositions for treating insomnia
Feb, 2025

(2 years from now)

US7658945 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Apr, 2027

(4 years from now)

US8242131 PURDUE PHARMA Methods of treating middle-of-the-night insomnia
Aug, 2029

(6 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 23 November, 2011

Treatment: Method for treating insomnia; Method of treating middle-of-the-night insomnia

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of INTERMEZZO before it's patent expiration?
More Information on Dosage

INTERMEZZO family patents

31

United States

8

Korea, Republic of

3

Canada

3

Japan

2

Brazil

2

South Africa

2

Australia

2

New Zealand

2

Mexico

2

China

2

European Union

1

Hong Kong

1

Israel

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in